Myelodysplastic Syndrome (MDS) Drugs Global Market Report 2024

The global myelodysplastic syndrome (mds) drugs market has grown strongly in recent years. It will grow from $3.23 billion in 2023 to $3.47 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to aging population, advancements in targeted therapies, clinical trials, increased awareness.

The global myelodysplastic syndrome (mds) drugs market is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to genomic research, immunotherapies, global expansion of healthcare, biomarker identification. Major trends in the forecast period include personalized medicine, combinatorial therapies, symptom management, data sharing and collaboration.

The growing exposure to cancer treatments, such as chemotherapy and radiation, is expected to stimulate the expansion of the myelodysplastic syndrome (MDS) drug market in the coming years. Chemotherapy involves the use of medications to eliminate cancer cells, while radiation therapy employs high doses of radiation to target cancer cells and reduce tumor sizes. Both chemotherapy drugs and radiation treatments can negatively affect the bone marrow's stem cells, which play a crucial role in generating new blood cells. This disruption in normal cell production can lead to the development of MDS. Myelodysplastic syndrome (MDS) drugs offer various benefits in managing and treating MDS, a group of disorders characterized by abnormal blood cell production in the bone marrow. For instance, the European Society of Radiation Oncology (ESTRO) estimates that there will be a 16% increase in the number of radiotherapy treatment courses by 2025 based on projected cancer distributions. Consequently, the rising exposure to cancer treatments, including chemotherapy and radiation, is a driving force behind the growth of the myelodysplastic syndrome (MDS) drugs market.

The surge in myeloid leukemia cases is projected to advance the expansion of the myelodysplastic syndrome (MDS) drug treatment market. Myeloid leukemia is a type of cancer originating in the bone marrow, impacting the cells responsible for generating various blood cell types. Myelodysplastic syndrome (MDS) drugs aim to enhance bone marrow function by addressing the root causes of leukemia, thereby reducing the risk of complications associated with low blood cell counts, decreasing the necessity for chemotherapy and transplants, and ultimately improving survival rates for individuals with myelodysplastic syndrome (MDS). For example, the American Cancer Society estimates that there will be around 20,380 cases and 11,310 deaths in adults from acute myeloid leukemia (AML) in 2023. Consequently, the increasing incidence of myeloid leukemia is a key driver behind the myelodysplastic syndrome (MDS) drug market's growth.

The myelodysplastic syndrome (MDS) drug market faces obstacles in its growth due to the high costs associated with treatment during the forecast period. Elevated treatment expenses can create financial barriers, hindering patients' access to essential MDS drugs. In some cases, individuals may be unable to afford treatment altogether, potentially resulting in unmet medical needs. For instance, the American Hospital Association, a professional organization, reported a 2.1% increase in hospital prices over the year leading up to February 2022. Consequently, the substantial cost of treatment serves as a hindrance to the growth of the myelodysplastic syndrome (MDS) drug market.

Prominent companies operating in the myelodysplastic syndrome (MDS) drug market are dedicated to the development of novel products aimed at enhancing patient outcomes, addressing specific customer demands, and adapting to the evolving healthcare landscape. Drug approvals, like venetoclax (VENCLEXTA), play a pivotal role in ensuring the safety and efficacy of MDS drugs for managing this group of bone marrow disorders. For example, in July 2021, AbbVie Inc., a US-based pharmaceutical company, received a Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for venetoclax (VENCLEXTA) in combination with azacitidine. This designation was for the potential treatment of adult patients with untreated intermediate, high, and very high-risk myelodysplastic syndromes (MDS). A distinguishing feature of VENCLEXTA and VENCLYXTO is their ability to attach to and inhibit the B-cell lymphoma-2 (BCL-2) protein, which regulates the apoptosis, or natural cell death, process in various blood malignancies.

In April 2021, Servier Laboratories, a France-based pharmaceutical company, completed its acquisition of Agios Pharmaceuticals' oncology business, encompassing its commercial, clinical, and research-stage oncology portfolio. The acquisition, valued at over $2 billion, serves to strengthen Servier's position in the oncology sector and diversify its precision medicine offerings. Agios Pharmaceuticals Inc., a US-based biopharmaceutical company, is dedicated to developing treatments for rare genetic diseases, including myelodysplastic syndrome (MDS).

Major players in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2023. The regions covered in myelodysplastic syndrome (MDS) drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the myelodysplastic syndrome (MDS) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of drugs used for myelodysplastic syndrome (MDS) treatment include chemotherapy and immunomodulatory drugs. Chemotherapy is a cancer treatment approach that employs anti-cancer medications to eliminate cancerous cells. These drugs can be administered via oral or parenteral routes to manage conditions such as refractory cytopenia with multilineage dysplasia, refractory anemia, and refractory anemia with ringed sideroblasts. Various healthcare settings, including hospitals, clinics, and ambulatory surgical centers, are involved in the distribution and administration of these drugs.

This report provides myelodysplastic syndrome (MDS) drugs market statistics, including myelodysplastic syndrome (MDS) drugs industry global market size, regional shares, competitors with a myelodysplastic syndrome (MDS) drugs market share, detailed myelodysplastic syndrome (MDS) drugs market segments, market trends and opportunities and any further data you may need to thrive in the myelodysplastic syndrome (MDS) drugs industry. This myelodysplastic syndrome (MDS) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The myelodysplastic syndrome (MDS) drugs market consists of sales of vidaza (azacitidine), dacogen (decitabine) and reblozyl (luspatercept-aamt). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.